RECRUITING

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer and other malignancies of the head and neck undergoing radiation therapy and/or receiving systemic therapy before surgery. An hpMRI is like a standard MRI but involves the use of an imaging contrast agent called hyperpolarized 13-C-pyruvate. Diagnostic procedures, such as hpMRI, may predict a patient's response to treatment and may help plan the best treatment.

Official Title

Pilot Study of Metabolic Guidance for Therapy in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck

Quick Facts

Study Start:2020-08-12
Study Completion:2027-05-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04589624

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Be willing and able to provide informed consent
  2. * Be informed of the investigational nature of this study
  3. * Be diagnosed with thyroid cancer and other malignancies of the head and neck with intent for treatment
  1. * Have a history of severe claustrophobia
  2. * Have electrically, magnetically or mechanically activated implants that would preclude magnetic resonance imaging (MRI)
  3. * Have a history of cardiac arrhythmia
  4. * Have an allergy to Gadavist intravenous contrast
  5. * Estimated glomerular filtration rate (eGFR) \< 30
  6. * If female, be pregnant or breast feeding at time of consent

Contacts and Locations

Study Contact

Stephen Y Lai
CONTACT
713-792-6528
sylai@mdanderson.org

Principal Investigator

Stephen Y Lai
PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center

Study Locations (Sites)

M D Anderson Cancer Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

  • Stephen Y Lai, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-08-12
Study Completion Date2027-05-31

Study Record Updates

Study Start Date2020-08-12
Study Completion Date2027-05-31

Terms related to this study

Additional Relevant MeSH Terms

  • Thyroid Gland Carcinoma